Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q3 FY23 results · Oct–Dec 2022
Supriya Lifescience reported revenue from operations of ₹105.14 crore (down 10.1% from Q3 FY22) and net profit of ₹9.52 crore (down 76.0% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a standalone basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 105.14 | 117.00 | −10.1% | 112.17 | −6.3% |
| Other income | 2.56 | 5.44 | −52.9% | 2.60 | −1.6% |
| Total income | 107.70 | 122.44 | −12.0% | 114.78 | −6.2% |
| Profit before tax | 12.64 | 40.07 | −68.4% | 27.42 | −53.9% |
| Net profit for the period | 9.52 | 39.64 | −76.0% | 16.86 | −43.6% |
| EPS, basic (₹) | 1.18 | 4.93 | −76.1% | 2.10 | −43.8% |
| Net margin (%) | 9.1 | 33.9 | 15.0 |
Standalone
- Filed with BSE
- 15 Feb 2023, 15:31 IST
- Board meeting
- 14 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE